Evonik will continue to optimize its global methionine production setup for MetAMINO® (DL-methionine) in the third and fourth quarters of 2025. The implementation of several technical measures requires a shutdown of the production facilities for methionine and its precursors for 6-7 weeks each at Evonik's Singapore site in August and September and at its Antwerp site in September and October 2025.

In Singapore, the maintenance schedule of a raw material supplier necessitates an early shutdown in Q3. Evonik will synchronize this with the catalyst exchange in its methionine production and take this opportunity to further improve the energy efficiency and CO₂ emissions of the plant.

In Antwerp, Evonik will also combine a catalyst exchange with the continuation of the measures begun in May to reduce nitrogen, sulphur, and CO₂ emissions. During the shutdown of the methionine facilities for 6-7 weeks in September and October, the Evonik Antwerp site will implement further milestones from its climate roadmap and make the site’s utilities infrastructure fit for the future. These upgrades are major enablers that contribute to further reductions in the carbon footprint of Evonik’s production facilities.

“With our global production setup for MetAMINO®, we continue to ensure supply security for our customers worldwide for the years to come. MetAMINO® also has a product carbon footprint that is approximately 35% lower than the calculated global industry average*. This is the result of our constant efforts to optimize our assets”, said Dirk Hoehler, head of the amino acids business of Evonik’s Animal Nutrition business line, in a press release.

*Methodology for global industry average excluding Evonik: estimated internally by Evonik‘s market intelligence, technology and life cycle assessment experts. Industry methionine sources include DL-methionine, L-methionine and methionine hydroxy analogue (MHA). Global Warming Potential is estimated accounting for the higher bioavailability of methionine in MetAMINO® versus MHA.